Mersana Therapeutics, Inc. (MRSN) financial statements (2021 and earlier)

Company profile

Business Address 840 MEMORIAL DRIVE
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments25510070115
Cash and cash equivalents255626027
Short-term investments 371088
Receivables  01
Other undisclosed current assets3242
Total current assets:25910174118
Noncurrent Assets
Operating lease, right-of-use asset113
Property, plant and equipment2232
Long-term investments and receivables   10
Long-term investments   10
Other noncurrent assets2120
Total noncurrent assets:156413
TOTAL ASSETS:27310879131
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities24162310
Accounts payable87113
Accrued liabilities169127
Deferred revenue45
Debt03  
Deferred rent credit  0
Deferred revenue and credits22
Contract with customer, liability46
Other liabilities00  
Other undisclosed current liabilities1   
Total current liabilities:30246932
Noncurrent Liabilities
Long-term debt and lease obligation155  
Long-term debt, excluding current maturities54  
Operating lease, liability101
Liabilities, other than long-term debt00029
Deferred revenue and credits29
Deferred rent credit  0
Other liabilities00  
Total noncurrent liabilities:155029
Total liabilities:45297061
Stockholders' equity
Stockholders' equity attributable to parent22878970
Common stock0000
Additional paid in capital508271173168
Accumulated other comprehensive income (loss) 0(0)(0)
Accumulated deficit(280)(192)(164)(98)
Total stockholders' equity:22878970
TOTAL LIABILITIES AND EQUITY:27310879131

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Gross profit:1421118
Operating expenses(89)(72)(76)(57)
Operating loss:(88)(30)(66)(40)
Nonoperating income0211
Investment income, nonoperating02  
Interest and debt expense(0)(0)  
Loss before gain (loss) on sale of properties:(88)(28)(64)(39)
Other undisclosed net income00  
Net loss available to common stockholders, diluted:(88)(28)(64)(39)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(88)(28)(64)(39)
Other comprehensive income (loss)(0)00(0)
Comprehensive loss, net of tax, attributable to parent:(88)(28)(64)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: